Elsevier

The Lancet

Volume 378, Issue 9785, 2–8 July 2011, Pages 3-4
The Lancet

Comment
Global control of diabetes: information for action

https://doi.org/10.1016/S0140-6736(11)60604-1Get rights and content

References (13)

There are more references available in the full text version of this article.

Cited by (25)

  • Single-cell analysis of platelets from patients with periodontitis and diabetes

    2023, Research and Practice in Thrombosis and Haemostasis
  • Gender difference in diabetes related excess risk of cardiovascular events: When does the ‘risk window’ open?

    2017, Journal of Diabetes and its Complications
    Citation Excerpt :

    The excess risk for cardiovascular diseases (CVD) associated with diabetes is greater in women than in men, as confirmed by several prospective studies as well as meta-analyses (Norhammar & Schenck-Gustafsson, 2013; Peters, Huxley, Sattar, & Woodward, 2015; Peters, Huxley, & Woodward, 2014a; Peters, Huxley, & Woodward, 2014b; Regensteiner et al., 2015). Although not completely explained, this gender difference has obvious implications in the attempt to optimize preventative and therapeutic interventions due to the well known increase in CV risk conferred by diabetes (Huxley, Barzi, & Woodward, 2006; International Diabetes Federation, 2013; Soedamah-Muthu et al., 2004) and the difference in the incidence rate of the disease between men and women (Peters et al., 2015; Tobias, 2011). Nonetheless, it is yet to be well defined whether the difference between genders is the same for each CV event (i.e. coronary heart disease, stroke, chronic heart failure, lower extremity amputations, etc.) and whether the ‘gender gap’ remains constant through the entire lifespan.

  • Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: A pooled analysis of 96 population-based studies with 331 288 participants

    2015, The Lancet Diabetes and Endocrinology
    Citation Excerpt :

    Population-based health surveys in different countries and at different times have also used different biomarkers for glycaemia and diabetes, and thus define diabetes differently. The variety of biomarkers and definitions creates a challenge in consistently analysing diabetes prevalence across countries and over time, and in measuring what proportion of people with diabetes are diagnosed and receive effective treatments for diabetes and its complications.1,16,17 Therefore, there is a need to understand how the use of different biomarkers and definitions affects the identification of diabetes cases and the resulting estimates of population prevalence.

  • The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

    2013, Journal of Diabetes and its Complications
    Citation Excerpt :

    Diabetes is an increasing public health problem. The UN General Assembly has recognized that diabetes poses risks to well-being worldwide and has calculated that diabetes prevalence has risen by about 7% per decade, from 8.3% in 1980 to 9.8% in 2008 among men, and from 7.5% to 9.2% among women (Tobias, 2011). The number of adults with T2DM worldwide has more than doubled in the last 30 years, rising from 153 million in 1980 to 347 million in 2008 (Danaei et al., 2011).

View all citing articles on Scopus
View full text